Comprehensive Chronic Wound Care Science & Research
We heal 95% of chronic wounds in 90 days.
Population that suffers from chronic wounds in the U.S.
Growth in patients per year in the U.S.
Double-digit growth In U.S. treatment costs in the last 2 years.
About Regenerex
Comprehensive chronic wound care solutions.
Regenerex is providing complete care solutions that are attractive to all healthcare systems, and are an exceptional fit in performance-based healthcare models.
- Chronic becomes healable
- Successful trials
- Marketplace proven
- Predictable outcomes
- Predictable treatment costs
- Patented technology
Xcellderma™ sterile wound cream
Simple to apply, unit-dose sterile wound cream that treats a wide variety of chronic and acute wounds, featuring QBx™ technology in an over-the-counter (OTC) protocol.
Regenerex Woundcare Closure Program
Regenerex Woundcare Closure Program is a turnkey chronic wound healthcare program for states, Federal agencies, managed care organizations, and managed care provider groups. The program increases positive outcomes and uses fixed cost modeling to help payers better manage chronic wound healthcare costs.
Accelerex™ specialized sterile wound creams
Sterile wound creams specifically designed for commercial use in the treatment of chronic wounds. Accelerex™ Accelerex™ with Copper Accelerex™ with Honey Accelerex™ with Collagen
Protocol Products
Wound Wash Enzymatic Debridement Exudate Management Dressings Compression Dressings Offloading Devices
Patented QBx Technology
Healing Chronic Wounds
Regenerex products are used to heal multiple types of chronic wounds with an astounding efficacy rate of 95% in 90 days or less.
Regenerex Video Series
Applications
Healing Chronic Wounds
Regenerex products are used to heal multiple types of chronic wounds with an astounding efficacy rate of 95% in 90 days or less.
Diabetic Foot Ulcers
Summary
Venous Ulcers
Summary
Pressure Ulcers
Summary
Acute Wounds
Summary
Burn Wounds
Summary
Arterial Ulcers
Summary
Research Studies
Regenerex Technology Case Studies
First-generation wound care technologies, including those evaluated in studies conducted by 3M™, utilized PHI™ as the active component. PHI™ was designed to downregulate elevated protease activity in the wound bed, thereby supporting the body’s natural healing processes. Clinical outcomes demonstrated wound closure rates of approximately 70–83% with PHI™ alone.
Second-generation technology, Regenerex QBx™, incorporates the same core bioactive components as PHI™ while integrating additional complementary mechanisms of action. In addition to protease modulation, Regenerex QBx™ disrupts biofilm barriers, reduces pro-inflammatory cytokines, and promotes growth factor activity. Collectively, these enhancements have been shown to achieve wound closure rates of up to 95% within 90 days.
3M™ is a trademark of 3M Company.
Art of Balancing the Wound Micro-Environment: How to Treat Chronic Wounds in Another Way
Hoekstra Study An Observational Study of the Use of QBx™ Impregnated Dressing in the Treatment of Wounds
Tissue Viability Consultancy Services, Ltd. StudyOur Culture
Continuous Innovation
Our research, testing, and perfecting of our technology for over 30 years has earned patented IP backed by patient studies.
Today, our multi-factor approach is able to close 95% of non-responding, chronic wounds in 90 days or less. Regenerex is the only company who can make that claim.
Vision
To work with healthcare systems to implement Regenerex technologies, protocols, and products to close chronic wounds, reduce healthcare costs, and dramatically improve the lives and outcomes of patients.
Mission
To eliminate over 95% of the chronic wound issues, world-wide.
Motto
Making "chronic" in wound care a thing of the past.
Chris Hendrix, D.P.M.
Clinical Director
Tasha D. Kennon, RN, BS, CDCES, CDFS
Clinical Training Director
Our Executive Team
Get to know our Clinical Directors
Learn more about our clinical directors and their years of clinical experience using protease down-regulating technologies.
Make Regenerex a part of your healthcare system
Reach out to our team to find out how to onboard Regenerex in your healthcare ecosystem.
A Randomized Double-Blind Study to Evaluate the Effects of MMP Down Regulators, on Two Different Topical Preparations, on the Healing of Partial Thickness Wounds in Healthy Human Volunteers.
Alvaraz Study A first generation PHI™ study